NP / PA
Familycareofhartford Corp
Familycareofhartford Corp was paid $1.77M by Medicaid between Sep 2020 and Dec 2024, across 35 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 55% of everything it billed.
33Billing provider infoFAMILYCAREOFHARTFORD CORP
HARTFORD, CT 06106
HARTFORD, CT 06106
33aNPI1134686777assigned 03/01/2019
33bProvider typeFamily Nurse Practitioner
28Total paid$1.77M
24GClaims44,514
24DCodes billed35
24AFirst – last monthSep 2020 – Dec 2024
Compared with peers
Next to other Family Nurse Practitioner providers in Connecticut
Rank by total paid#12 of 108
Median peer was paid$32K
This provider vs. median54×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 1,157 | $33K | |
| 2021 | 5,483 | $219K | |
| 2022 | 9,647 | $359K | |
| 2023 | 13,283 | $524K | |
| 2024incomplete | 14,944 | $634K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 55% | 13,367 | 8,481 | $979K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 17% | 5,872 | 3,929 | $309K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 9.4% | 1,511 | 1,176 | $166K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 4.9% | 1,164 | 946 | $87K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 3.4% | 2,389 | 1,810 | $60K |
| 99195 | 2.6% | 2,728 | 2,098 | $46K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 1.4% | 319 | 248 | $25K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 2,406 | 1,453 | $21K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 165 | 136 | $14K |
| 99406 | <1% | 1,211 | 819 | $11K | |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 156 | 75 | $9K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 235 | 144 | $9K |
23 more codes
| 94760 | <1% | 6,528 | $8K | |
| 99173 | <1% | 1,484 | $7K | |
| 81000 | <1% | 1,612 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 55 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 89 | $2K |
| 90656 | <1% | 137 | $2K | |
| 90686 | <1% | 115 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 141 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 101 | $675.54 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 108 | $567.38 |
| 94664 | <1% | 82 | $455.40 | |
| 99407 | <1% | 17 | $310.18 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 628 | $260.10 |
| 93000 | <1% | 18 | $147.68 | |
| 80305 | <1% | 26 | $122.40 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 80 | $95.26 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 118 | $47.30 |
| J3490 | Unclassified drugs | <1% | 123 | $35.75 |
| 85014 | <1% | 20 | $32.48 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 85 | $8.73 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 46 | $3.99 |
| 99072 | 0% | 1,328 | $0.00 | |
| 99000 | 0% | 50 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialZUBAIRI, MUHAMMAD (PRESIDENT)